You are here
L2 DIAGNOSTICS LLC
UEI: GKA7VH5LFR25
# of Employees: 15
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
New Serodiagnostics for Isocyanate Exposure, A Major Cause of Occupational Asthma
Amount: $202,698.00DESCRIPTION (provided by applicant): Occupational exposures are estimated to account for 9-15% of adult asthma cases. Among the most common causes of occupational asthma are isocyanates, reactive chem ...
STTRPhase I2008Department of Health and Human Services National Institutes of Health -
EGFR Peptides as Vaccines in Anti-Tumor Immunity
Amount: $277,711.00DESCRIPTION (provided by applicant): The focus of our in Phase I studies is the development of a novel peptide-based vaccination strategy designed to overcome immune tolerance to Epidermal Growth Fact ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
Modified HER-2 Tumor Antigens for Vaccination in Cancer
Amount: $1,127,668.00DESCRIPTION (provided by applicant): Breast cancer remains one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are a ...
STTRPhase II2006Department of Health and Human Services National Institutes of Health -
Antivirals Targeting Flavivirus Envelope Proteins
Amount: $998,224.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide ...
STTRPhase I2006Department of Health and Human Services National Institutes of Health -
Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis
Amount: $169,964.00DESCRIPTION (provided by applicant): Once thought to be on the decline, tuberculosis (TB) still remains a major global health problem today. With an estimated eight million new cases and two million d ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Broad-Spectrum Therapeutic Human Antibodies for Dengue Virus Infections
Amount: $190,425.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop antibody therapeutics to treat life-threatening flavivirus infections. Our working hypothesis is that antibodies rec ...
STTRPhase I2006Department of Health and Human Services National Institutes of Health -
Antivirals Targeting Flavivirus Envelope Proteins
Amount: $998,224.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop therapeutic antivirals to treat life-threatening flavivirus infections. Enfuvirtide, a clinically successful peptide ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Modified HER-2 Tumor Antigens for Vaccination in Cancer
Amount: $1,127,670.00DESCRIPTION (provided by applicant): Breast cancer remains one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are a ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
Broad-Spectrum Therapeutic Human Antibodies for Dengue Virus Infections
Amount: $190,425.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop antibody therapeutics to treat life-threatening flavivirus infections. Our working hypothesis is that antibodies rec ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Virulence Typing of Pseudomonas Clinical Isolates
Amount: $767,447.00DESCRIPTION (provided by applicant): Pseudomonas aeruginosa is an opportunistic bacterial pathogen responsible for a significant proportion of serious hospital acquired infections. The organism has i ...
STTRPhase II2005Department of Health and Human Services National Institutes of Health
